Transplant center directory

Banner University Medical Center's Hematopoietic Cell Therapy and Transplant Program started in 1998 and has been Foundation for Accreditation of Cellular Therapy-accredited since 2000. The Program was certified for its first Immune Effector Cell Therapy in 2018, and currently offers multiple Immune Effector Cell Therapy options both inpatient and outpatient. The Arizona Cancer Center is an National Cancer Institute-designated Comprehensive Cancer Center. Research is conducted in cooperation with National Institutes of Health, Social Work Oncology Group and Children's Oncology Group. A team of experienced physicians, nurses, social workers, laboratory and support staff work together to provide the highest level of care to adult and pediatric patients and their families.

This center has been performing allogeneic transplants since 1988 and has been an NMDP/Be The Match transplant center since September 1993.

Banner University Medical Center Tucson - Adults

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 31 patients.

The actual 1-year survival of these patients is 77.4%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 60.9% and 89.9%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Banner University Medical Center Tucson - Pediatrics

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 33 patients.

The actual 1-year survival of these patients is 90.8%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 72.5% and 95.9%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.